The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022

Simple item page
dc.contributor.authorVeitch, Dallas P.
dc.contributor.authorWeiner, Michael W.
dc.contributor.authorMiller, Melanie
dc.contributor.authorAisen, Paul S.
dc.contributor.authorAshford, Miriam A.
dc.contributor.authorBeckett, Laurel A.
dc.contributor.authorGreen, Robert C.
dc.contributor.authorHarvey, Danielle
dc.contributor.authorJack, Clifford R., Jr.
dc.contributor.authorJagust, William
dc.contributor.authorLandau, Susan M.
dc.contributor.authorMorris, John C.
dc.contributor.authorNho, Kwangsik T.
dc.contributor.authorNosheny, Rachel
dc.contributor.authorOkonkwo, Ozioma
dc.contributor.authorPerrin, Richard J.
dc.contributor.authorPetersen, Ronald C.
dc.contributor.authorRivera Mindt, Monica
dc.contributor.authorSaykin, Andrew
dc.contributor.authorShaw, Leslie M.
dc.contributor.authorToga, Arthur W.
dc.contributor.authorTosun, Duygu
dc.contributor.authorAlzheimer’s Disease Neuroimaging Initiative
dc.contributor.departmentRadiology and Imaging Sciences, School of Medicine
dc.date.accessioned2024-06-25T13:13:34Z
dc.date.available2024-06-25T13:13:34Z
dc.date.issued2024
dc.description.abstractThe Alzheimer's Disease Neuroimaging Initiative (ADNI) aims to improve Alzheimer's disease (AD) clinical trials. Since 2006, ADNI has shared clinical, neuroimaging, and cognitive data, and biofluid samples. We used conventional search methods to identify 1459 publications from 2021 to 2022 using ADNI data/samples and reviewed 291 impactful studies. This review details how ADNI studies improved disease progression understanding and clinical trial efficiency. Advances in subject selection, detection of treatment effects, harmonization, and modeling improved clinical trials and plasma biomarkers like phosphorylated tau showed promise for clinical use. Biomarkers of amyloid beta, tau, neurodegeneration, inflammation, and others were prognostic with individualized prediction algorithms available online. Studies supported the amyloid cascade, emphasized the importance of neuroinflammation, and detailed widespread heterogeneity in disease, linked to genetic and vascular risk, co-pathologies, sex, and resilience. Biological subtypes were consistently observed. Generalizability of ADNI results is limited by lack of cohort diversity, an issue ADNI-4 aims to address by enrolling a diverse cohort.
dc.eprint.versionFinal published version
dc.identifier.citationVeitch DP, Weiner MW, Miller M, et al. The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022. Alzheimers Dement. 2024;20(1):652-694. doi:10.1002/alz.13449
dc.identifier.urihttps://hdl.handle.net/1805/41870
dc.language.isoen_US
dc.publisherWiley
dc.relation.isversionof10.1002/alz.13449
dc.relation.journalAlzheimer's & Dementia
dc.rightsAttribution-NonCommercial 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourcePMC
dc.subjectAlzheimer's Disease Neuroimaging Initiative
dc.subjectAlzheimer's disease clinical trials
dc.subjectAlzheimer's disease subtypes
dc.subjectAmyloid
dc.subjectCerebrovascular disease
dc.subjectCo-pathologies
dc.subjectDiagnosis
dc.subjectDisease progression
dc.subjectGeneralizability
dc.subjectNeurodegeneration
dc.subjectNeuroinflammation
dc.subjectPlasma biomarkers
dc.subjectPrediction
dc.subjectResilience
dc.subjectTau
dc.titleThe Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Veitch2024Alzheimer-CCBYNC.pdf
Size:
4.86 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.04 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Policy Articles